$5.72
0.08 (+1.42%)
MannKind Corp (MNKD)
CAPS Rating:
A biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes and cancer.
A biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes and cancer.
Recs
I remain long-term negative on Mannkind due to the well-established problems with inhaled insulins. However, the product has solid efficacy data which at least positions it for a favorable review from the FDA. I expect the FDA to set safety standards for Technosphere which are virtually impossible to overcome in terms of time and resources. In the near-to-mid-term I'm positive at this price point.
I'm going to bet on a pullback, and exit at virtually the same price I entered.